Expanding opportunities through pharma & biotech partnerships

We are developing unique and differentiated cellular therapies based on regulatory T cells (Treg).

TxCell is the only company globally to be focusing exclusively on antigen-specific Tregs to fight autoimmunity and inflammation. We aim at being the first company in the world to put a CAR-Treg candidate in clinical development, by 2018.

We also aim at fully leveraging our technology and develop an array of CAR‑Tregs as broad as possible.

To achieve this goal, we are actively seeking to partner with world-leading industry players eager to revolutionize medicine.

TxCell brings over 15 years of pioneering work in the science of Tregs, as well as key in-house expertise for all major CAR-Treg development steps.

Our technology platform is versatile, multifaceted and fueled with various Treg populations and mechanisms of action (immune suppression and cytotoxicity). It has the potential to address autoimmune diseases (both T‑cell and B‑cell mediated) in an unprecedently targeted way.

TxCell - Partnering
TxCell - Partnering

Our partnership model is based on exclusive disease franchise deals.

These consist in an early R&D collaboration (4-5 years) with the objective of initiating multiple new CAR-Treg programs within a defined disease scope (e.g. gastrointestinal diseases, rheumatic diseases, neurology, solid organ transplantation, dermatology, metabolic diseases).

For each discovery program, the partner will have an option to get an exclusive development and commercialization license.

With this model, TxCell has the potential to earn significant revenues through upfront and milestone payments, licensing fees and royalties. This strategy will also allow us to spread risks and costs and to optimize both time to market and market penetration.

TxCell intends to retain rights to certain niche/orphan indications and/or geographies.

Collaborate with TxCell

TxCell - Maud Bouvier

Our team is ready to meet with you to share our capabilities and discuss business opportunities. If you would like to partner, please contact Maud Bouvier, VP Business Development, through this form.

Academic Collaborations

TxCell works with world-leading academic institutions to enhance the development of its technology platform.

Academic collaborations can take various forms, from in-licensing agreements to strategic R&D collaborations.

In April 2016, TxCell entered into a strategic R&D collaboration with Ospedale San Raffaele (OSR) in Milan, Italy, one of the most prestigious research institutions in Europe in the field of cell and gene therapy.

This collaboration includes a development arm focused on Lupus Nephritis, as well as a research program dedicated to CAR-Treg biology.

The development part of the collaboration focuses on the non-clinical development of Chimeric-Antigen-Receptor engineered regulatory T (CAR-Treg) cells for the treatment of Lupus Nephritis.

More information on this program

In June 2016, TxCell entered into a strategic R&D collaboration agreement with the Lübeck Institute of Experimental Dermatology (LIED), a leading institution in the field of translational research on skin blistering diseases, part of the University of Lübeck in Germany.

This specific collaboration agreement covers the development of a CAR-Treg-based cellular immunotherapy for bullous pemphigoid, a rare, potentially fatal autoimmune disease characterized by tense inflammatory skin blisters and in some patients, erosions on mucous membranes.

More information on this program

In June 2016, TxCell signed an exclusive worldwide licensing agreement with Yeda Research and Development Co. Ltd., the technology transfer arm of the Weizmann Institute of Science in Rehovot, Israel.

The agreement grants TxCell exclusive worldwide right to a broad ‘umbrella’ patent covering all redirected, genetically engineered T regulatory cells (CAR-Tregs) and their use in the suppression of autoimmune and inflammatory diseases. This patent originated in the Weizmann Institute of Science laboratory of Professor Zelig Eshhar, who pioneered the CAR (Chimeric Antigen Receptor) approach.

In October 2016, TxCell entered into a strategic R&D collaboration agreement with the University of British Columbia (UBC) in Vancouver, Canada, a leading global center for multidisciplinary research and teaching.

This collaboration agreement covers the development of a CAR-Treg-based cellular immunotherapy for the prevention of graft rejection in the context of Solid Organ Transplantation (SOT).

More information on this program

In December 2016, TxCell has been granted an exclusive worldwide license to two patent families filed by the Center for Research in Transplantation and Immunology (CRTI) in Nantes, France.

These patents cover a new type of CD8+Tregs, which are non-cytotoxic and display a unique and highly immunosuppressive mechanism of action.

Collaborate with TxCell

TxCell - Maud Bouvier

If you would like to discuss a potential academic collaboration with TxCell, please contact Maud Bouvier, VP, Business Development, through our contact form.